On December 15, 2025, Eli Lilly formally submitted a New Drug Application for orforglipron, its next-generation, once-daily oral anti-obesity candidate. In two pivotal phase 3 trials involving more than 3,200 participants, orforglipron achieved mean body-weight reductions of up to 18.9% at 52 weeks versus placebo, with treatment-emergent adverse event rates comparable to placebo. The oral formulation leverages a small-molecule GLP-1 receptor agonist profile, positioning Lilly to capture patients who prefer pills over injectable therapies.

Orforglipron was granted a Commissioner's National Priority Review Voucher in November 2025, reducing the FDA target action date to within two months of application acceptance. This expedited pathway reflects the therapy’s potential to address a high-unmet medical need in obesity management and could lead to a regulatory decision by February 2026. Lilly’s regulatory team has already engaged with FDA reviewers on manufacturing and clinical sections to streamline the remaining review steps.

In October 2025, Lilly announced a commitment exceeding $1 billion to establish and upgrade manufacturing partnerships in India for small molecules, complex injectables and vials. Under this plan, Lilly will contract with three local firms to produce orforglipron API and final dosage forms, aiming to secure supply continuity for its global obesity and diabetes portfolio. Initial API batches are slated for completion by Q3 2026, with commercial launch readiness targeted for mid-2027.

Since its U.S. launch in mid-2024, Zepbound (tirzepatide) has captured approximately 27% of weekly GLP-1 obesity prescriptions, according to IQVIA data through November 2025. Lilly’s integrated marketing efforts and patient support programs have driven rapid uptake, with active patient counts exceeding 210,000. This robust performance underpins Lilly’s confidence in scaling orforglipron’s uptake once approved, leveraging established provider networks and reimbursement pathways.